LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis GBX 518.67 -16.33 (-3.05%) As of 04:39 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Oxford Biomedica Stock (LON:OXB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oxford Biomedica alerts:Sign Up Key Stats Today's Range 514▼ 53750-Day Range 426.50▼ 55952-Week Range 420▼ 952Volume39,678 shsAverage Volume1.03 million shsMarket Capitalization£629.97 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 818Consensus RatingModerate Buy Company Overview Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube. Read More Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OXB Stock News HeadlinesOxford BioMedica’s AI tools could cut development time by 80%, Jefferies saysOctober 23, 2026 | uk.finance.yahoo.comOXB Announces Appointment of Joachim Kreuzburg as Independent Non-Executive Director, Effective November 23, 2026October 16, 2026 | marketscreener.comMI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout. | Behind the Markets (Ad)Oxford BioMedica Appoints Former Sartorius CEO Joachim Kreuzburg as Non-Executive DirectorOctober 16, 2026 | uk.finance.yahoo.comOxford Biomedica vice chair increases shareholding with small market purchaseSeptember 29, 2026 | theglobeandmail.comOXB outlook maintained as client pipeline improves revenue visibilitySeptember 23, 2026 | uk.finance.yahoo.comVeeva Systems Vault CRM Extends Market Leadership As Another Top 20 Biopharma Chooses Veeva SystemsSeptember 23, 2026 | marketscreener.comMOxford Biomedica Advances Global Quality Transformation with Veeva Quality CloudSeptember 23, 2026 | tmcnet.comSee More Headlines OXB Stock Analysis - Frequently Asked Questions How have OXB shares performed this year? Oxford Biomedica's stock was trading at GBX 617 at the beginning of the year. Since then, OXB shares have decreased by 15.9% and is now trading at GBX 518.67. How were Oxford Biomedica's earnings last quarter? Oxford Biomedica plc (LON:OXB) announced its earnings results on Wednesday, September, 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter. Oxford Biomedica had a negative trailing twelve-month return on equity of 54.51% and a negative net margin of 23.23%. Read the conference call transcript. How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include Oxford BioMedica (OXBDF), Lloyds Banking Group (LLOY), Glencore (GLEN), Barclays (BARC), Vodafone Group Public (VOD), Rolls-Royce Holdings plc (RR.L) and Tesco (TSCO). Company Calendar Last Earnings9/23/2026Today11/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:OXB CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Price Target for Oxford BiomedicaGBX 818 High Price TargetGBX 950 Low Price TargetGBX 595 Potential Upside/Downside+57.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)GBX (31.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£143.51 million Net Margins-23.23% Pretax MarginN/A Return on Equity-54.51% Return on Assets-12.67% Debt Debt-to-Equity Ratio273.08 Current Ratio2.21 Quick Ratio1.67 Sales & Book Value Annual Sales£175.36 million Price / Sales3.59 Cash FlowGBX 172.52 per share Price / Cash Flow3.01 Book ValueGBX 67.70 per share Price / Book7.66Miscellaneous Outstanding Shares121,459,000Free FloatN/AMarket Cap£629.97 million OptionableNot Optionable Beta1.11 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (LON:OXB) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OXB Stock Alerts